Hirokazu Ogino, MD, PhD
Research Interest:
My focus of research during PhD course at Tokushima University was to understand the mechanisms of metastasis of lung cancer. Recently, as a medical oncologist and pulmonologist, I have also engaged in the functional analysis of stromal cells in tumor immunity, especially in thoracic malignancies.
From May 2019, I joined to Okada Lab to study and learn the up-to date skills, techniques and information about tumor immunology, and my current research is focused on developing novel engineered T cell therapies for glioma immunotherapy.
Outside the lab, I enjoy watching baseball, drinking beer and wine, and playing with my children.
2001-2010 Faculty of Medicine and Graduate School of Medical Sciences, The University of Tokushima, Japan (M.D.-Ph.D. Program)
2010-2014 St. Luke’s International Hospital, Tokyo, Japan, Resident,
2014-2015 Department of Respiratory Medicine & Rheumatology, Tokushima University Hospital, Clinical Fellow
2015-2019 Department of Respiratory Medicine & Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima Japan, Assistant Professor
2006 Presentation Award, The 10th Annual Meeting of the Japanese Association for Molecular Target Therapy of Cancer
2006 Presentation Award, The 11th Congress of the Asaian Pacific Society of Respirology
2008 The University of Tokushima Award for Medical Research
2015 Presentation Award, The 24th Annual Meeting of the Japanese Association for Metastasis Research
2017 JRS Young Investigator, European Respiratory Society International Congress 2017
2019 Daiichi Sankyo Foundation of Life Science, Fellowship program award
The clinical features of older patients with lung cancer in comparison with their younger counterparts.
Ogino H, Hanibuchi M, Sakaguchi S, Toyoda Y, Tezuka T, Kawano H, Kakiuchi S, Otsuka K, Saijo A, Azuma M, Nokihara H, Goto H, Nishioka Y.
Respir Investig. 2019;57:40-48.
Analysis of the Prognostic Factors of Extensive Disease Small-Cell Lung Cancer Patients in Tokushima University Hospital.
Ogino H, Hanibuchi M, Kakiuchi S, Saijo A, Tezuka T, Toyoda Y, Tobiume M, Otsuka K, Sakaguchi S, Goto H, Arisawa K, Nishioka Y.
J Med Invest. 2016;63:286-93.
Analysis of the clinical backgrounds of patients who developed respiratory acidosis under high-flow oxygen therapy during emergency transport.
Ogino H, Nishimura N, Yamano Y, Ishikawa G, Tomishima Y, Jinta T, Takahashi O,
Chohnabayashi N.
Acute Med Surg. 2015;3:26-31.
Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab.
Mitsuhashi A, Goto H, Saijo A, Trung VT, Aono Y, Ogino H, Kuramoto T, Tabata S, Uehara H, Izumi K, Yoshida M, Kobayashi H, Takahashi H, Gotoh M, Kakiuchi S, Hanibuchi M, Yano S, Yokomise H, Sakiyama S, Nishioka Y.
Nat Commun. 2015 Dec 4;6:8792.
E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor.
Ogino H, Hanibuchi M, Kakiuchi S, Trung VT, Goto H, Ikuta K, Yamada T, Uehara H, Tsuruoka A, Uenaka T, Wang W, Li Q, Takeuchi S, Yano S, Nishioka Y, Sone S.
Mol Cancer Ther. 2011;10:1218-28.
Follistatin suppresses the production of experimental multiple-organ metastasis by small cell lung cancer cells in natural killer cell-depleted SCID mice.
Ogino H, Yano S, Kakiuchi S, Muguruma H, Ikuta K, Hanibuchi M, Uehara H, Tsuchida K, Sugino H, Sone S.
Clin Cancer Res. 2008;14:660-7.
Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement.
Ogino H, Yano S, Kakiuchi S, Yamada T, Ikuta K, Nakataki E, Goto H, Hanibuchi M, Nishioka Y, Ryan A, Sone S.
Cancer Lett. 2008;265:55-66.